Soligenix, Inc. develops therapeutics and vaccines.  The Company researches treatments for gastrointestinal Graft-versus-Host disease and cancer, and develops vaccines for military and civilian applications.

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Current Report (Form 8-K | Period ending 2025-06-20)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Soligenix (SNGX US)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Current Report (Form 8-K | Period ending 2025-06-20)

Quarterly Report (Form 10-Q | Period ending 2025-03-31)

Annual Report to Security Holders (Form ARS | Period ending 2024-12-31)

Current Report (Form 8-K | Period ending 2025-03-25)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)